FY2024 · ended Jun 30, 2024 · Revenue $0, -100.0% YoY · Filed Mar 20, 2026
Benitec Biopharma Inc. (BNTC) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$16.6 million. As of Jun 30, 2026 it held $180.0 million in cash and investments and $762,000 in total debt.
Revenue
$0
-100.0% vs prior year
Net income (TTM)
$-41.54M
-22.8% vs year-ago TTM
Operating cash flow
$-16.52M
+30.0% vs prior year
Free cash flow
$-16.62M
+29.6% vs prior year
EPS (TTM)
$-0.93
+10.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
34.88M
+32.9% vs prior year
Net cash
$179.21M
FY 2026
Operating margin
-25441.3%
FY 2023
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BNTC (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Hayward, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1808898
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $75,000 | $73,000 |
| Operating income | -$51.2M | -$41.8M | -$22.5M | -$19.1M | -$17.9M |
| Net income | -$45.5M | -$37.9M | -$21.8M | -$19.6M | -$18.2M |
| Diluted EPS | -$0.98 | -$1.05 | -$1.22 | -$14.12 | -$37.88 |
| Operating cash flow | -$16.5M | -$23.6M | -$19.4M | -$18.0M | -$15.9M |
| Free cash flow | -$16.6M | -$23.6M | -$19.6M | -$18.0M | -$15.9M |
| Total assets | $182.6M | $99.6M | $52.2M | $4.5M | $6.0M |
| Total liabilities | $5.6M | $2.3M | $5.0M | $4.3M | $3.1M |
| Stockholders' equity | $177.0M | $97.3M | $47.2M | $202,000 | $2.9M |
| Cash and investments | $180.0M | $97.7M | $50.9M | $2.5M | $4.1M |
| Total debt | $762,000 | $849,000 | $284,000 | $559,000 | $811,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Auditor change
|
Sep 30, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Auditor change
|
Sep 24, 2026 | Sep 18, 2026 |
| 10-K | Annual report | Sep 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 14, 2026 | Sep 14, 2026 |
All 334 Benitec Biopharma Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.